Back to search

University of Patras

Exploring oncometabolism and exosomes towards in silico, in vitro and in vivo drug repurposing in glioblastoma mutliforme

Abstract

dc:description

In the era of precision oncology, clinical management of glioblastoma remains a major challenge, indicating an urgent need for novel drug targets and companion biomarkers in a multidisciplinary therapeutic strategy rationale. We and others appreciate that the elusive characterization of hypoxic and radioresistant glioblastoma cells is an important impediment to translational precision medicine. The purpose of the present study is to combine 1D and 3D data for in silico, in vitro, and in vivo drug repurposing, focusing on tumor bioenergetics and oncometabolism. The rationale of drug repurposing lies in the principles of molecular pharmacology, especially when biological redundancy and polypharmacology are considered. Both biological redundancy and polypharmacology are based on a molecular networking view of the cellular function, as they require, at first, protein-protein interactions. Putting the radioresistant cell in the spotlight, our approach is based on omics and 3D molecular structure data. We focus on disease-centric and at the same time, drug-centric repurposing of the only human paracaspase, MALT1, looking for allosteric inhibitors. We employed pharmacophore modeling and molecular docking to screen vast libraries of existing drugs and new chemical entities (NCEs), while balancing chemical diversity and drug-likeness, and next, the most promising ones were selected. Their allostery and inhibitory activity against MALT1, alongside their cytotoxicity were assessed in patient-derived glioblastoma spheroids. Drug-drug interaction risks were further explored upon CYP450-mediated inhibition profiling. Our findings allowed us to pinpoint promising candidates, exhibiting potent allosteric inhibition of MALT1 and selective cytotoxicity in MALT1-overexpressing glioblastoma spheroids. Our findings also highlight the potential of repurposing DPP-4 inhibitors, such as sitagliptin, for the treatment of glioblastoma. Additionally, exploring the interplay between MALT1 inhibition and EV-derived miRNAs, we highlight new avenues for understanding the molecular basis of glioblastoma progression and resistance. A mass spectrometry-based untargeted metabolomic analysis on plasma samples from glioblastoma patients was employed to delineate the role of metabolic remodeling in biological plasticity and, hence, disease severity. Following data processing and analysis, we established a bioenergetic profile coordinated by the mitochondrial function and redox state, lipids, and energy substrates. We propose that biological plasticity in glioblastoma is a mechanism of adaptation and resistance to treatment which is eloquently revealed by bioenergetics. As our work demonstrates, drug repurposing, guided by a comprehensive understanding of the tumor's metabolic state, holds promise for tailoring treatments to the right patient, with the right drug, at the right dose, and at the optimal time.

Degree

thesis:*
Grantor dc:publisher
University of Patras
Year dc:date
2025

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Bafiti, Paraskevi
  • Μπαφίτη, Παρασκευή

Subjects

dc:subject × 22

Rights

Language dc:language
eng

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/60144

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Bafiti, Paraskevi; Μπαφίτη, Παρασκευή. Exploring oncometabolism and exosomes towards in silico, in vitro and in vivo drug repurposing in glioblastoma mutliforme. University of Patras, 2025. http://hdl.handle.net/10442/hedi/60144